Monash scientists find first antibiotic resistance gene inside bacterial spores

Clostridioides difficile is one of the most persistent hazards in modern hospitals. The bacterium lives quietly in the gut until antibiotics wipe out the competing microbes that normally keep it in check, and then it multiplies, producing toxins that cause diarrhea and, in frail or already ill patients, infections that can be fatal. Its most important survival tool is not the actively growing cell but the spore, a dormant, armour like form that can sit on a bed rail, a floor or a piece of medical equipment for months and then revive when it is swallowed.

That biology has shaped hospital cleaning for decades. Bleach, hydrogen peroxide based products and high temperature laundry cycles are chosen specifically because they are supposed to destroy C. difficile spores. Now researchers at Monash University in Melbourne have found that the bacterium has acquired a gene that makes its spores harder to kill, and they say it is the first time an antibiotic resistance gene has been shown to arise in the spore form of a bacterium rather than in the ordinary, growing cell.

The work, published in Nature Communications, centres on a gene the team named CdmecA. It is a homologue, meaning a close relative, of mecA, the gene that made Staphylococcus aureus resistant to methicillin and helped turn MRSA into a global problem. In C. difficile the gene does something different and, according to the authors, unexpected: the protein it produces functionally replaces SpoVD, a conserved protein the bacterium needs in order to build spores. With that substitution in place, spores keep forming even when the bacterium is exposed to antibiotics that would normally shut sporulation down.

Antimicrobial resistance is already one of the most serious threats in medicine. Drug resistant infections kill more than 1.2 million people each year, and the World Health Organization lists antimicrobial resistance as a major global health threat. The new finding adds a dimension that resistance surveillance has largely ignored: the durable, transmissible spore, a cell type that moves genes between patients, between hospitals and between environments.

Key Facts

Monash University announced on September 30, 2026 that its researchers had identified CdmecA in Clostridioides difficile. Medical Xpress reported on September 29 that the study, published in Nature Communications under DOI 10.1038/s41467-026-75594-5, shows the bacterium has picked up a gene that gives its dormant spores a free pass against antibiotics and cleaning products. The lead researcher is Dena Lyras, interim dean of the Monash Sub Faculty of Biomedical and Psychological Sciences and director of the Monash Biomedicine Discovery Institute.

The gene is a homologue of Staphylococcus aureus mecA, described in the paper as one of the most globally burdensome resistance genes. Nature Communications reported on July 15 that acquiring CdmecA allows C. difficile to bypass the anti sporulation effect of cephamycins, a group of antibiotics, by functionally replacing the spore building protein SpoVD. The result is restored sporulation and spores that are phenotypically distinct, meaning they look and behave differently from ordinary spores.

The discovery began with an accident. Researchers trying to grow C. difficile found their laboratory bacterium multiplied normally but could not make spores. The growth medium, it turned out, contained a cephamycin. That unintended experiment revealed that cephamycins can block sporulation. The Age reported on September 29 that Lyras described the moment as the discovery of a group of antibiotics that actually stopped sporulation in its tracks.

The bacteria then answered back. The Age reported on September 29 that in about 10 per cent of the strains the team examined, the sporulation blocking strategy simply did not work, and that this subset of strains carried the new resistance gene. Xinhua reported on September 30 that the gene produces a protein that replaces a key spore building protein, allowing the bacterium to make tougher spores that can survive hospital grade cleaning products and high laundry temperatures.

The consequences for containment are concrete. Lyras said that killing C. difficile spores requires around half an hour of contact with bleach, and that even 200 hours of irradiation does not leave a population 100 per cent dead. The paper also reports that mecA is prevalent across C. difficile strains and across other pathogenic, gut and environmental spore formers, and the team confirmed that MecA can co opt sporulation in Clostridium perfringens, a different pathogen.

Analysis

What this really means is that antibiotic resistance can no longer be treated as a property of the growing bacterial cell alone. The textbook model says a bacterium survives an antibiotic because it carries a gene that protects the machinery of an actively dividing cell. CdmecA breaks that model. It protects reproduction itself, the process by which the bacterium builds a dormant particle designed to outlast disinfectants, heat, drying and time. The resistance gene does not simply shield a cell; it changes the cell type the bacterium produces.

The second judgement concerns where the pressure comes from. The cephamycin result suggests a class of antibiotics can suppress spore formation, which would be valuable in a hospital, because fewer spores mean fewer opportunities for the bacterium to persist on surfaces and travel between patients. A gene that restores sporulation under those conditions shows that any new control strategy creates selection pressure for a counter strategy. As Lyras put it, antibiotics are helping bacteria evolve in ways researchers had not anticipated, and some strains are not only better at tolerating drugs but also able to make new versions of themselves that survive better in environments where cleaning products are commonly applied.

Third, the prevalence data matter more than any single strain. If mecA is already widespread among C. difficile and among other spore formers, the mechanism may not be a rare curiosity confined to one laboratory sample. The confirmation in Clostridium perfringens shows the trick travels, which fits the underlying biology: SpoVD is a conserved protein, so a gene that can stand in for it has a broad set of potential hosts.

None of this means hospital cleaning has stopped working. It means the margin for error has narrowed, and that surveillance which tests only growing bacteria will miss a resistance mechanism that operates in the dormant, hardest to culture stage of the organism.

Why It Matters

For hospitals the practical risk is amplification. Spores are the main way these pathogens spread between people and through hospitals, homes and the environment, as first author Yogitha Srikhanta, a postdoctoral research fellow at the Monash Biomedicine Discovery Institute, has said. Tougher spores that tolerate hospital grade disinfectants and high laundry temperatures make that spread harder to interrupt, at exactly the point where infection control depends on interrupting it.

For patients the arithmetic is unforgiving. C. difficile causes diarrhea that can be deadly for people who are already ill, and it commonly infects the gut after antibiotic treatment. A strain that keeps making spores while under antibiotic pressure can persist in a patient, contaminate a ward and seed new infections long after the original course of treatment ends. Antimicrobial resistance, already linked to more than 1.2 million deaths a year, would then have a new and unusually durable route of transmission.

For the wider field, the finding reshapes how resistance is studied. The paper argues that spores deserve attention as vehicles of resistance genes, precisely because of their durability and transmissibility. A gene carried inside a spore can survive conditions that would kill a growing cell and can be delivered to a new host later, which reframes the spore not only as a survival stage but as part of the resistance problem itself.

Next Up

The Monash team is now investigating ways to target the spores and deal with this new type of resistance. One line of work is the SpoVD pathway itself, the conserved protein that CdmecA replaces, since the interaction between the two proteins is a potential point of attack. Another is diagnostics, because a gene that changes spore behaviour may be invisible to tests focused on actively growing cells.

Public health attention will also turn to how widely CdmecA circulates, since the study reports that mecA is prevalent across C. difficile strains and other pathogenic, gut and environmental spore formers. Confirming that reach in real hospital settings is the next practical question. Until then, the work stands as the first documented case of antibiotic resistance arising in the spore form of a bacterium, a finding that changes what infection control teams and drug developers have to plan for.